TORONTO, ON -- (Marketwired) -- 09/03/14 -- Nevada-based Modern Mobility Aids, Inc. (PINKSHEETS: MDRM) (the "Company"), is pleased to announce the appointment of Baseer U. Khan, MD, FRCS©, Toronto, Ontario, as Chief Medical Director of the Company effective immediately. In this role, Dr. Khan will also chair the Medical Advisory Committee of the Company. He will coordinate the medical expertise and recommendations of current board members and recruit other advisory members that reflect some of the many areas of science and medicine to which cannabis is increasingly relevant.
"As a medical device and biopharma Company, it is imperative that we have a Chief Medical Director as part of our management team," says CEO Kenneth Pinckard. The role of the CMD will be dominant in assisting management in marketing, securing senior human resource professionals for the medical marijuana sector and interfacing with health, safety and government regulators. The role will also place Dr. Khan in a pivotal position for identifying stand alone and synergistic business opportunities for the Company in this rapidly evolving and growing industry.
Dr. Khan will lead the Company in research areas relevant to the medical marijuana sector and help develop ethical marketing strategies while building a library of global information as it affects the many applications of cannabis through industry conferences, study groups, associate organizations, and regulatory bodies. "As a strategic member of our management team, Dr. Khan will work to establish MDRM as a leading authority in this space and aspire to develop a mutually advantageous and supportive relationship with Health Canada," Mr. Pinckard emphasized.
Dr. Khan uniquely brings both medical and business expertise to MDRM. Clinically, Dr. Khan is an internationally recognized surgeon, researcher, and consultant. He is an Assistant Professor, University of Toronto and Executive Lead Physician, Eye Institute, Southlake Regional Hospital, Newmarket Ontario. Corporately, Dr. Khan founded and established the largest private ophthalmic practice in Toronto (Clarity Eye Institute), and is a managing partner and CIO of Oneview Procurement Solutions.
About Modern Mobility Aids, Inc.
Modern Mobility Aids, Inc. was first incorporated under the laws of the State of Nevada on December 19, 2007, under the name of Glider Inc. Its original business plan was to sell and distribute products for mobility-challenged individuals. The Company changed its name to Modern Mobility Aids, Inc. on April 22, 2010. In February 2014, the business focus of the Company evolved with a rapid expansion strategy in the life sciences and healthcare industry, with a focus on production of Medical Marijuana. A mandate was created to acquire companies within the biopharma and alternative medicine sectors targeting both innovative research and development as well as scalable licensed, manufacturing capacity in three niche market segments.
This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). In particular, when used in the preceding of discussion, the words "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. There are no guarantees or assurances that any proposals, initiatives or negotiations will result in what the Company had originally intended. Any investment made into Modern Mobility Aids, Inc., would be classified as speculative and risky. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the Company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the Company's financial reports and filings.